Published On: Wed, Sep 13th, 2017

Targacept, Inc. (NASDAQ:TRGT) Analyst Coverage


A number of investment brokers have recently updated their price targets on shares of Targacept, Inc. (NASDAQ:TRGT).

Most recent broker ratings

05/01/2015 – Targacept, Inc. had its “hold” rating reiterated by analysts at Zacks.

11/05/2014 – Targacept, Inc. had its “neutral” rating reiterated by analysts at MKM Partners. They now have a USD 2 price target on the stock.

07/30/2014 – Targacept, Inc. had its “neutral” rating reiterated by analysts at Ladenburg Thalmann. They now have a USD 3 price target on the stock.

12/17/2013 – Targacept, Inc. had its “” rating reiterated by analysts at Deutsche Bank. They now have a USD 4 price target on the stock.

The share price of Targacept, Inc. (NASDAQ:TRGT) was up +0.00% during the last day of trading, with a day high of 0.00. 0 shares were traded during the last session.

The stock’s 50 day moving average is 0.38 and its 200 day moving average is 0.37.Targacept, Inc. has a 52-week low of 0.31 and a 52-week high of 1.35.

Catalyst Biosciences, Inc., formerly Targacept, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness. The Company’s advanced program is a coagulation Factor VIIa variant, CB 813d, that has completed a Phase I clinical trial in severe hemophilia A and B patients. In addition to its lead Factor VIIa program, it has approximately two other coagulation factors, a Factor IX variant, CB 2679d/ISU 304, that is in advanced preclinical development, and a Factor Xa variant that has reached the advanced lead preclinical-stage of development.